Boston Scientific has entered into a definitive agreement to acquire devicemaker Penumbra in a cash and stock transaction valued at approximately $14.5 billion.
Boston Scientific leaders said Penumbra’s portfolio of vascular and neurovascular technologies will expand the company’s offerings in fast-growing treatment areas, according to a Jan. 15 news release from Boston Scientific.
The acquisition is expected to close in 2026, pending shareholder and regulatory approvals.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
